CNCR vs. AMOM
Compare and contrast key facts about Loncar Cancer Immunotherapy ETF (CNCR) and QRAFT AI-Enhanced U.S. Large Cap Momentum ETF (AMOM).
CNCR and AMOM are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. CNCR is a passively managed fund by Exchange Traded Concepts that tracks the performance of the Loncar Cancer Immunotherapy Index. It was launched on Oct 13, 2015. AMOM is an actively managed fund by Exchange Traded Concepts. It was launched on May 21, 2019.
Performance
CNCR vs. AMOM - Performance Comparison
Loading graphics...
CNCR vs. AMOM - Yearly Performance Comparison
| 2026 (YTD) | |
|---|---|
CNCR Loncar Cancer Immunotherapy ETF | 0.00% |
AMOM QRAFT AI-Enhanced U.S. Large Cap Momentum ETF | -5.77% |
Returns By Period
CNCR
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
AMOM
- 1D
- -0.09%
- 1M
- -3.41%
- YTD
- -0.99%
- 6M
- -1.25%
- 1Y
- 23.73%
- 3Y*
- 19.23%
- 5Y*
- 7.75%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
CNCR vs. AMOM - Expense Ratio Comparison
CNCR has a 0.79% expense ratio, which is higher than AMOM's 0.75% expense ratio.
Return for Risk
CNCR vs. AMOM — Risk / Return Rank
CNCR
AMOM
CNCR vs. AMOM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and QRAFT AI-Enhanced U.S. Large Cap Momentum ETF (AMOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Loading graphics...
Sharpe Ratios by Period
| CNCR | AMOM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | — | 0.95 | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.33 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | — | 0.59 | — |
Dividends
CNCR vs. AMOM - Dividend Comparison
CNCR has not paid dividends to shareholders, while AMOM's dividend yield for the trailing twelve months is around 0.09%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
CNCR Loncar Cancer Immunotherapy ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
AMOM QRAFT AI-Enhanced U.S. Large Cap Momentum ETF | 0.09% | 0.09% | 0.00% | 0.47% | 0.72% | 0.74% | 24.31% | 5.51% |
Drawdowns
CNCR vs. AMOM - Drawdown Comparison
The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum AMOM drawdown of -39.68%. Use the drawdown chart below to compare losses from any high point for CNCR and AMOM.
Loading graphics...
Drawdown Indicators
| CNCR | AMOM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | 0.00% | -39.68% | +39.68% |
Max Drawdown (1Y)Largest decline over 1 year | — | -13.10% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -39.68% | — |
Current DrawdownCurrent decline from peak | 0.00% | -7.66% | +7.66% |
Average DrawdownAverage peak-to-trough decline | 0.00% | -11.04% | +11.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 3.90% | — |
Volatility
CNCR vs. AMOM - Volatility Comparison
Loading graphics...
Volatility by Period
| CNCR | AMOM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | — | 8.82% | — |
Volatility (6M)Calculated over the trailing 6-month period | — | 17.65% | — |
Volatility (1Y)Calculated over the trailing 1-year period | 0.00% | 25.25% | -25.25% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 0.00% | 23.51% | -23.51% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 0.00% | 24.98% | -24.98% |